Yuetiva Deming

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1203011/publications.pdf

Version: 2024-02-01

49 papers	2,327 citations	331259 21 h-index	329751 37 g-index
62 all docs	62 docs citations	62 times ranked	4064 citing authors

#	Article	IF	Citations
1	A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nature Neuroscience, 2017, 20, 1052-1061.	7.1	330
2	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica, 2016, 131, 925-933.	3.9	262
3	Early increase of CSF sTREM2 in Alzheimerâ€™s disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. Molecular Neurodegeneration, 2019, 14, 1.	4.4	253
4	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
5	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	192
6	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	5.8	170
7	Polygenic risk score of sporadic lateâ€onset Alzheimer's disease reveals a shared architecture with the familial and earlyâ€onset forms. Alzheimer's and Dementia, 2018, 14, 205-214.	0.4	109
8	Sex-specific genetic predictors of Alzheimerâ€™s disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
9	Higher CSF sTREM2 and microglia activation are associated with slower rates of betaâ€amyloid accumulation. EMBO Molecular Medicine, 2020, 12, e12308.	3.3	73
10	Sex differences in the genetic predictors of Alzheimerâ€™s pathology. Brain, 2019, 142, 2581-2589.	3.7	65
11	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	3.3	64
12	The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathologica, 2020, 139, 45-61.	3.9	51
13	Assessment of the Genetic Architecture of Alzheimerâ€™s Disease Risk in Rate of Memory Decline. Journal of Alzheimer's Disease, 2018, 62, 745-756.	1.2	45
14	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. Neurobiology of Aging, 2016, 37, 208.e1-208.e9.	1.5	44
15	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. PLoS Genetics, 2017, 13, e1007045.	1.5	40
16	Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. Communications Biology, 2021, 4, 63.	2.0	28
17	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. Expert Opinion on Therapeutic Targets, 2018, 22, 587-598.	1.5	27
18	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571.	0.9	27

#	Article	IF	Citations
19	Reversal of Established Traumatic Brain Injury-Induced, Anxiety-Like Behavior in Rats after Delayed, Post-Injury Neuroimmune Suppression. Journal of Neurotrauma, 2014, 31, 487-497.	1.7	25
20	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. Scientific Reports, 2016, 6, .	1.6	25
21	TMEM106B: a strong FTLD disease modifier. Acta Neuropathologica, 2014, 127, 419-422.	3.9	24
22	Role of ABCA7 loss-of-function variant in Alzheimer's disease: a replication study in Europeanâ€“Americans. Alzheimer's Research and Therapy, 2015, 7, 73.	3.0	24
23	Identification of plexin A4 as a novel clusterin receptor links two Alzheimerâ€™s disease risk genes. Human Molecular Genetics, 2016, 25, 3467-3475.	1.4	21
24	Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. Frontiers in Neuroscience, 2018, 12, 209.	1.4	21
25	SORL1 variants across Alzheimerâ€™s disease European American cohorts. European Journal of Human Genetics, 2016, 24, 1828-1830.	1.4	20
26	Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. Alzheimer's Research and Therapy, 2018, 10, 86.	3.0	18
27	Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. BMC Neurology, 2016, 16, 217.	0.8	12
28	An APOE -independent cis -eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. Neurobiology of Aging, 2018, 66, 178.e1-178.e8.	1.5	12
29	Exploring common genetic contributors to neuroprotection from amyloid pathology. Brain Communications, 2022, 4, fcac066.	1.5	10
30	CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN. Experimental Gerontology, 2017, 90, 83-89.	1.2	7
31	CSF sphingomyelin metabolites in Alzheimerâ€™s disease, neurodegeneration, and neuroinflammation. Alzheimer's and Dementia, 2021, 17, .	0.4	4
32	Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 299-314.	0.4	3
33	CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12167.	1.2	2
34	Diet and APOE as moderators of the relationship between trimethylamine Nâ€oxide and biomarkers of Alzheimer's disease and glial activation. Alzheimer's and Dementia, 2021, 17, e051827.	0.4	2
35	Protective genetic variants in the MS4A gene cluster modulate microglial activity. Alzheimer's and Dementia, 2020, 16, e039431.	0.4	1
36	Principal components from untargeted CSF metabolomics associated with tau. Alzheimer's and Dementia, 2020, 16, e046065.	0.4	1

#	Article	IF	Citations
37	CSF polygenic risk AD biomarkers predict brain amyloid and free recall. Alzheimer's and Dementia, 2021, 17, .	0.4	1
38	O4-05-06: A potential endophenotype for Alzheimer's disease: Cerebrospinal fluid clusterin. , 2015, 11, P280-P280.		0
39	P3â€097: SORL1 Variants Across Alzheimerâ€™s Disease Cohorts in European Americans. Alzheimer's and Dementia, 2016, 12, P857.	0.4	0
40	O2â€10â€06: A Common Allele in SPI1 Lowers Risk and Delays Age at Onset for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P253.	0.4	0
41	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P252.	0.4	0
42	[O1â€“11â€“03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P218.	0.4	0
43	P2â€105: NOMINATION OF NOVEL CANDIDATE GENES FOR FAMILIAL LATE ONSET ALZHEIMER DISEASE AFTER EVALUATION OF GENEâ€BASED FAMILYâ€BASED METHODS. Alzheimer's and Dementia, 2018, 14, P709.	0.4	0
44	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
45	S1-02-01: REVIEW OF GWAS GENES AND POLYGENIC RISK SCORES. , 2018, 14, P198-P198.		0
46	Identification of blood eQTLs for AD risk loci. Alzheimer's and Dementia, 2020, 16, e043801.	0.4	0
47	Multimodal genomeâ€wide metaâ€analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. Alzheimer's and Dementia, 2020, 16, e046009.	0.4	0
48	Exploring genetic contributors to neuroprotection from AD pathologies: A genomeâ€wide association study. Alzheimer's and Dementia, 2020, 16, e046417.	0.4	0
49	Association of anticholinergic medication and AD biomarkers among cognitively normal late middleâ€age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP). Alzheimer's and Dementia, 2021, 17, .	0.4	0